

Détails publications Dr ETIENNE Nicolas

1. Disseminated Spiroplasma apis Infection in Patient with Agammaglobulinemia, France.
Emerg Infect Dis. 2018 Dec;24(12):2382-2386.
Etienne N, Bret L, Le Brun C, Lecuyer H, Moraly J, Lanternier F, Hermine O, Ferroni A, Lecuit M, Pereyre S, Beven L, Lortholary O.
2. HIV infection and COVID-19: risk factors for severe disease.
AIDS. 2020 Oct 1;34(12):1771-1774.
Etienne N, Karmochkine M, Slama L, Pavie J, Batisse D, Usubillaga R, Letembet VA, Brazille P, Canoui E, Slama D, Joumaa H, Canoui-Poitrine F, Segaux L, Weiss L, Viard JP, Salmon D; COVID-19 ID Team.
3. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes
Orphanet J Rare Dis. 2023 Apr 30;18(1):100.
Groh M, Rohmer J, **Etienne N**, Abou Chahla W, Baudet A, Chan Hew Wai A, et al.
4. High Frequency of Specific Polysaccharide Antibody Deficiency in Adults With Unexplained, Recurrent and/or Severe Infections With Encapsulated Bacteria.
Clinical Infectious Diseases. 2023 Mar 4;76(5):800–8.
Stabler S, Lamblin C, Gaillard S, Just N, Mihailescu M, Viget N, ..., **Etienne N**, et al.
5. C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis.
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1347-1351.e3.
Leurs A, Chenivresse C, Lopez B, Gibier JB, Clément G, Groh M, Copin MC, Staumont-Sallé D, Mortuaire G, Balquet MH, Dezoteux F, Bautin N, Buchdahl AL, Le Gouellec N, **Etienne N**, Terriou L, Dubucquoi S, Labalette M, Morell-Dubois S, Maillard-Lefebvre H, Lambert M, Hachulla E, Launay D, Kahn JE, Hatron PY, Lefèvre G.
6. Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.
Oncoimmunology. 2020 Apr 7;9(1):1722022.
Scanvion Q, Béné J, Gautier S, Grandvilllemin A, Le Beller C, Chenaf C, **Etienne N**, Brousseau S, Cortot AB, Mortier L, Staumont-Sallé D, Morschhauser F, Forestier A, Groh M, Launay D, Hachulla E, Labalette M, Kahn JE, Lefèvre G.
7. Hypereosinophilic syndromes.
Rev Prat. 2019 Sep;69(7):767-773.
Groh M, Lefèvre G, Ackermann F, **Etienne N**, Kahn JE.
8. Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome.
J Allergy Clin Immunol Pract. 2020.
Ledoult E, Groh M, Kahn JE, Trauet J, Bouaziz JD, Caristan A, Cottin V, Dubucquoi S, **Etienne N**, Golden C, Guillaume-Jugnot P, Hachulla É, Launay D, Machelart I, De Masson A, Molinet T, Morati-Hafsaoui C, Puget M, Roumier M, Terriou L, Meresse B, Dendooven A, Copin MC, Dubois R, Labalette M, Lefèvre G; CEREO—French National Reference Center for Hypereosinophilic Syndromes.

9. "Idiopathic Eosinophilic Vasculitis": Another Side of Hypereosinophilic Syndrome? A Comprehensive Analysis of 117 Cases in Asthma-Free Patients.
J Allergy Clin Immunol Pract. 2020 Apr;8(4):1329-1340.e3.
Lefèvre G, Leurs A, Gibier JB, Copin MC, Staumont-Sallé D, Dezoteux F, Chenivresse C, Lopez B, Terriou L, Hachulla E, Launay D, **Etienne N**, Labalette M, DeGrootte P, Pontana F, Quemeneur T, Hatron PY, Schleinitz N, Viillard JF, Hamidou M, Martin T, Morati-Hafsaoui C, Groh M, Lambert M, Kahn JE; CEREO—French National Reference Center for Hypereosinophilic Syndromes.
10. IgG4-related disease and hypereosinophilic syndrome: Overlapping phenotypes.
Autoimmun Rev. 2021 Sep;20(9):102889.
Moussiegt A, Müller R, Ebbo M, Grados A, Graveleau J, Ackermann F, Bachmeyer C, Bernit E, Blanche P, Canoui E, Chaix F, Costedoat-Chalumeau N, Grootte P, **Etienne N**, Fior R, Flamarion E, Kennel T, Launay D, Lerolle N, Limal N, Loustau V, Menage E, Moulis G, Papo T, Pouchot J, Quemeneur T, Roumier M, Tchérakian C, Lefèvre G, Rebours V, Kahn JE, Schleinitz N, Groh M; CEREO; French IgG4-RD Study Group.
11. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study.
J Infect. 2021 Feb;82(2):e1-e4.
Salmon-Ceron D, Slama D, De Broucker T, Karmochkine M, Pavie J, Sorbets E, **Etienne N**, Batisse D, Spiridon G, Baut VL, Meritet JF, Pichard E, Canoui-Poitaine F; APHP COVID-19 research collaboration.
12. Self-reported loss of smell without nasal obstruction to identify COVID-19. The multicenter Coranosmia cohort study.
J Infect. 2020 Oct;81(4):614-620.
Salmon Ceron D, Bartier S, Hautefort C, Nguyen Y, Nevoux J, Hamel AL, Camhi Y, Canoui-Poitaine F, Verillaud B, Slama D, Haim-Boukobza S, Sourdeau E, Cantin D, Corré A, Bryn A, **Etienne N**, Rozenberg F, Layese R, Papon JF, Bequignon E; APHP COVID-19 research collaboration.
13. Protein-losing Enteropathy as a Complication and/or Differential Diagnosis of Common Variable Immunodeficiency
J Clin Immunol. [Internet]. 2022 Jun 23 [cited 2022 Aug 7]; Available from: <https://link.springer.com/10.1007/s10875-022-01299-1>
Lefèvre G, Germain N, Vignes S, Séguy D, Stabler S, **Etienne N**, et al. Protein-losing Enteropathy as a Complication and/or Differential Diagnosis of Common Variable Immunodeficiency.
14. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFR α -positive myeloid neoplasm with eosinophilia: Data from 151 patients
Am J Hematol. 2020 Nov;95(11):1314–23.
Rohmer J, Couteau-Chardon A, Trichereau J, Panel K, Gesquiere C, Ben Abdelali R, **et al.**
15. Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort.
BMC Infect Dis. 2019 Dec;19(1):278.
the DAT'AIDS STUDY GROUP, Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, **et al.**
16. HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥ 60 : a relative survival analysis in the French Dat'AIDS cohort.
BMJ Open. 2019 Jan;9(1):e024841.
Hentzien M, Dramé M, Delpierre C, Allavena C, Cabié A, Cuzin L, **et al.**

17. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
Journal of Antimicrobial Chemotherapy. 2019 Mar 1;74(3):754–60.
Cuzin L, Pugliese P, Katlama C, Bani-Sadr F, Ferry T, Rey D, **et al.**
18. **E-poster ECCMID 2020**
HIV infection and COVID-19 : risk factors for severe disease
19. **Poster JNI 2020**
Facteurs de risques de formes sévères de COVID-19 au cours de l'infection par le VIH
20. **22th IOM Congress 2018**
Disseminated Spiroplasma apis infection in an agammaglobulinemic patient
21. **Participation au groupe rédactionnel - fiche ORPHANET 2018**
Urgences des syndromes hyperéosinophiliques
https://www.orpha.net/data/patho/Emg/Int/fr/SyndromeHypereosinophilique_FR_fr_EMG_ORPHA168956.pdf
22. **Participation au groupe rédactionnel - HAS 2022**
PNDS sur les syndromes hyperéosinophiliques
https://has-sante.fr/upload/docs/application/pdf/2022-06/pnds_she_document_complet.pdf